EE19 Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study
Abstract
Authors
C Ajala Zapata L Villa
C Ajala Zapata L Villa
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now